Caitlin Kontulis
Director of Finance/CFO at PHIO PHARMACEUTICALS CORP.
Net worth: 7 237 $ as of 2024-03-30
Profile
Caitlin Kontulis is currently working as the Secretary, VP-Finance & Administration at Phio Pharmaceuticals Corp.
Previously, she worked as the Interim Chief Accounting Officer at Galena Biopharma, Inc. She completed her graduate degree from Northeastern University in 2008 and her undergraduate degree from Bryant University in 2007.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-29 | 10,643 ( 0.44% ) | 7 237 $ | 2024-03-30 |
Caitlin Kontulis active positions
| Companies | Position | Start |
|---|---|---|
| PHIO PHARMACEUTICALS CORP. | Director of Finance/CFO | - |
Former positions of Caitlin Kontulis
| Companies | Position | End |
|---|---|---|
Galena Biopharma, Inc.
 Galena Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Galena Biopharma, Inc. is a biopharmaceutical company, which develops and commercializes hematology and oncology therapeutics that address unmet medical needs. The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Its products include Abstral sublingual tablets and Zuplenz oral soluble film. The company was founded by Craig Mello on April 3, 2006 and is headquartered in San Ramon, CA. | Comptroller/Controller/Auditor | - |
Training of Caitlin Kontulis
| Northeastern University | Graduate Degree |
| Bryant University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| PHIO PHARMACEUTICALS CORP. | Health Technology |
| Private companies | 1 |
|---|---|
Galena Biopharma, Inc.
Galena Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Galena Biopharma, Inc. is a biopharmaceutical company, which develops and commercializes hematology and oncology therapeutics that address unmet medical needs. The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Its products include Abstral sublingual tablets and Zuplenz oral soluble film. The company was founded by Craig Mello on April 3, 2006 and is headquartered in San Ramon, CA. | Health Technology |
- Stock Market
- Insiders
- Caitlin Kontulis
